Charles J. Schneider, MD, FACP, discusses the overall prognosis of patients with anal carcinoma.
Charles J. Schneider, MD, FACP, a clinical professor of Medicine at the Abramson Cancer Center at Perelman Center for Advanced Medicine, discusses the overall prognosis of patients with anal carcinoma.
Schneider recently gave a presentation on the subject during the NCCN 2022 Annual Conference.
Currently, anal carcinoma is rare and has a low mortality rate. However, the lower incidence of mortality comes after years of increasing mortality in the space, according to Schneider. The incidence increased by roughly 2.7% and the mortality rate increasing by roughly 3.1% year over year.
A preventative strategy for anal carcinoma is the human papillomavirus (HPV) vaccination, and Schneider explains that as more children are vaccinated, the rates of anal carcinoma and mortality may decrease.
0:07 | The incidence and mortality are rather low. But, despite the cancer being a rare malignancy, both incidence and mortality had been increasing between 1990 up until about the year of 2010. With incidence increasing by about 2.7% per year and mortality by about 3.1% per year. So, hopefully, HPV vaccination in children ages 12 and older will eventually lead to, hopefully a plateau of that rising incidence and mortality, and hopefully a decrease. But that's going to take a while, you know, a decade or longer since the HPV effect takes years on the canal.
The Impact of the Gut Microbiome in Young Patients With Colorectal Cancer
February 15th 2021In season 2, episode 2 of Targeted Talks, Cathy Eng, MD, speaks with Benjamin Weinberg, MD, about the gut microbiome, and how the presence of certain microbiota impact the onset and intensity of disease as well as the potential response to certain treatments.
Listen